基本信息
浏览量:2
职业迁徙
个人简介
David’s academic research team discovered the first C8-linked sequence-selective DNA-interactive PBD dimer which reached Phase II clinical trials in the US and UK in the early 2010s for the treatment of haematological cancers. PBD dimers are now used as the payload component for Antibody-Drug Conjugates (ADCs) in development by a number of companies world-wide as cancer therapies. After successful clinical trials, Loncastuximab tesirine (ADCT-402; Lonca-TTM), under development by ADCT Ltd, reached the IND stage with the FDA in 2020 and is expected to be approved for Diffuse Large B-cell lymphoma (DLBCL) in 2021.
In 2000, David co-founded the oncology biotech company Spirogen Ltd to commercialize the PBD dimer technology, acting as its CSO until 2011. The company was acquired by AstraZeneca/Medimmune in 2013. After moving to King’s College London in 2012, David worked on next-generation sequence-selective DNA-interactive ADC payloads in his academic laboratory, which led to foundation of the spin-out company Femtogenix Ltd in 2015 for which he still acts as CSO. In 2013, David co-founded another King’s spin-out company, Transcriptogen Ltd, which specializes in novel transcription factor inhibitors for the treatment of a wide range of human cancers.
During his academic career, David has supervised over 50 PhD students and numerous postdoctoral research fellows, has been the PI of several major Programme Grants from Cancer Research UK, and is author of ~200 publications in medicinal chemistry/chemistry journals and books. His textbook, Chemistry and Pharmacology of Anticancer Drugs, is used by undergraduates, postgraduates and cancer researchers in both industry and academia, and the Second Edition was published in 2021. He is also Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry which has now published over 75 volumes.
In between his undergraduate pharmacy degree and PhD studies, David completed his pre-registration pharmacy training at the Charing Cross Teaching Hospital (London). He is a registered pharmacist in the UK, and still practices to maintain his clinical skills. He is accredited to offer patients a range of Advanced NHS Services.
David was awarded the Academic Pharmacist of the Year prize from the PHARMAs in 2007, and was awarded Fellowships of the Royal Pharmaceutical Society and the Academy of Pharmaceutical Sciences in 2009.
In 2000, David co-founded the oncology biotech company Spirogen Ltd to commercialize the PBD dimer technology, acting as its CSO until 2011. The company was acquired by AstraZeneca/Medimmune in 2013. After moving to King’s College London in 2012, David worked on next-generation sequence-selective DNA-interactive ADC payloads in his academic laboratory, which led to foundation of the spin-out company Femtogenix Ltd in 2015 for which he still acts as CSO. In 2013, David co-founded another King’s spin-out company, Transcriptogen Ltd, which specializes in novel transcription factor inhibitors for the treatment of a wide range of human cancers.
During his academic career, David has supervised over 50 PhD students and numerous postdoctoral research fellows, has been the PI of several major Programme Grants from Cancer Research UK, and is author of ~200 publications in medicinal chemistry/chemistry journals and books. His textbook, Chemistry and Pharmacology of Anticancer Drugs, is used by undergraduates, postgraduates and cancer researchers in both industry and academia, and the Second Edition was published in 2021. He is also Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry which has now published over 75 volumes.
In between his undergraduate pharmacy degree and PhD studies, David completed his pre-registration pharmacy training at the Charing Cross Teaching Hospital (London). He is a registered pharmacist in the UK, and still practices to maintain his clinical skills. He is accredited to offer patients a range of Advanced NHS Services.
David was awarded the Academic Pharmacist of the Year prize from the PHARMAs in 2007, and was awarded Fellowships of the Royal Pharmaceutical Society and the Academy of Pharmaceutical Sciences in 2009.
研究兴趣
论文共 73 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Anthony Cheung,Alicia M Chenoweth,Annelie Johansson,Roman Laddach,Naomi Guppy, Jennifer Trendell, Benjamina Esapa, Antranik Mavousian, Blanca Navarro-Llinas,Syed Haider, Pablo Romero-Clavijo,Ricarda M Hoffmann,
Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Benjamina Esapa, Jiexuan Jiang,Anthony Cheung,Alicia Chenoweth,David E Thurston,Sophia N Karagiannis
Cancersno. 6 (2023): 1845-1845
John A. Hartley, Anzu Hamaguchi,Marissa Coffils, Christopher R.H. Martin,Marie Suggitt,Zhizhi Chen, Stephen J. Gregson,Luke A. Masterson,Arnaud C. Tiberghien, Janet M. Hartley,Christopher Pepper,Thet Thet Lin,
crossref(2023)
John A. Hartley, Anzu Hamaguchi,Marissa Coffils, Christopher R.H. Martin,Marie Suggitt,Zhizhi Chen, Stephen J. Gregson,Luke A. Masterson,Arnaud C. Tiberghien, Janet M. Hartley,Christopher Pepper,Thet Thet Lin,
crossref(2023)
Cancer Researchno. 12_Supplement (2022): 1750-1750
CANCER RESEARCHno. 12 (2022)
引用0浏览0引用
0
0
Cancer Researchno. 12_Supplement (2022): 6334-6334
George Procopiou,Paul J. Jackson,Daniella M. di Mascio,Jennifer L. Auer, Paolo Andriollo, Ilona Pysz,Khondaker M. Rahman,Keith R. Fox,David E. Thurston
Cancer Researchno. 12_Supplement (2022): 1749-1749
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn